Supplementary Table 2. Genes regulated by RASSF2A.

Table 1. Attribute profile clustering of differentially expressed genes between S3-C and T4-2

Table 1. Upregulated genes (ratio>10  n=10) in HT-29 5M21 cells versus parental HT-29 STD human colon cancer cells  and their corresponding GenBank accession numbers

Table 2. Regulated genes (ratio>2  n=28) in K18Y-TATI tumor xenografts versus HT-29 5M21 tumor xenografts at 41 days post inoculation of the cancer cells in SCID mice  and their corresponding GenBank accession numbers

Table 1 Name and function of genes selected

Table S1. Up-regulation Gene List in AT-MSC-Hepa; Of the 1639 genes with a >/= 10-fold alteration in expression  1252 genes were up-regulated. Up regulated genes belonged to families of metabolic enzymes  such as alcohol dehydrogenase  UDP glucuronosyltransferase and serine protease inhibitor  and liver marker genes  such as glucose-6-phosphatase and keratin 8

Table S2.  Down-regulation Gene List in AT-MSC-Hepa; Of the 1639 genes with a >/= 10-fold alteration in expression  387 were down-regulated. Genes that were down-regulated genes after hepatic differentiation of AT-MSCs include cyclin B2 and E2F1

Table 1. Liver function genes that were up-regulated in adipose tissue-derived mesenchymal stem cells (AT-MSC)-Hepa.

Table 2c Genes differentially expressed (RMA and MAS 5 overlaps) between the subgroups

Table 2a Genes differentially expressed (RMA and MAS 5 overlaps) between the subgroups

Table 2b Genes differentially expressed (RMA and MAS 5 overlaps) between the subgroups

Table 2d Genes differentially expressed (RMA and MAS 5 overlaps) between the subgroups

Table 6. Expression analysis of the cell cycle genes in ACG. Tissue samples from the ACG of controls (N=34) and SZ (N=45) were analyzed by qPCR. FC Ratio--fold change ratios represent the ratio of geometric means for each gene to the three housekeeping genes in SZ/control (+) and in control/SZ ( ) values. SZtotalFall the subjects with SZ. SZOFF (N=10)-subjects with SZ  whose neuroleptic treatment was discontinued for at least 4 weeks prior to death.